UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A wave of selling from retail investors has pulled Wendy's stock lower. This guide explains why that crowd dynamic co...
Your Social Security statement holds more than a number. Learn how to access it, read the earnings history and benefi...
Markets brace for a potential 2026 downturn as labor data cools. A five-ETF framework, marketed as the cockroach port...
SpaceX reportedly trims its IPO ambitions, signaling a lower target valuation looming. This article breaks down what ...
At 73, retirees face mandatory minimum distributions that can push income into higher tax brackets. The average 73-ye...
Ford tumbled 7% intraday and Tesla slid 4% in a sentiment-driven retreat. Analysts say the fade stems from profit-tak...
A fictional case study shows how fame, branding, and sudden leadership shifts test personal finances. Learn actionabl...
As inflation stays in focus for 2026, investors are rethinking retirement allocations. A diversified commodity ETF of...
A free cash flow ETF is delivering a surprising edge in 2026, outperforming the S&P 500 as investors rotate toward ca...
Global dividend payments in Q3 2025 surged to a record, signaling the largest dividend payout history and fueling ren...
June trading has investors juggling AI-driven hype with real earnings signals. This guide breaks down what’s moving m...